SCHEMBL1121674

SCHEMBL1121674

CC(=O)CSc1cccs1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 6/20 0.53
RAB9A P51151 6/20 0.53
HPGD P15428 3/20 0.51
MAPT P10636 3/20 0.51
ALDH1A1 P00352 7/20 0.49
SMN1; SMN2 Q16637 2/20 0.49
FBP1 P09467 1/20 0.45
HTT P42858 2/20 0.44
MEN1 O00255 3/20 0.41
KMT2A Q03164 3/20 0.41
PRNP P04156 1/20 0.41
NPSR1 Q6W5P4 1/20 0.41
RXFP1 Q9HBX9 1/20 0.41
POLB P06746 2/20 0.38
LMNA P02545 1/20 0.38
CES2 O00748 1/20 0.38
CES1 P23141 1/20 0.38
HSD17B3 P37058 1/20 0.38
PKM P14618 1/20 0.38
DAO P14920 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8639480 0.85 NPC1 (0.50) NPC1RAB9AHPGDMAPTALDH1A1
SCHEMBL2213224 0.82 HPGD (0.56) NPC1RAB9AHPGDMAPTALDH1A1
SCHEMBL1520869 0.81 NPC1 (0.53) NPC1RAB9AHPGDMAPTALDH1A1
SCHEMBL6703333 0.80 KMT2A (0.53) NPC1RAB9AHPGDMAPTALDH1A1
SCHEMBL11181260 0.79 NPC1 (0.51) NPC1RAB9AHPGDMAPTALDH1A1
SCHEMBL8579088 0.79 HPGD (0.54) NPC1RAB9AHPGDMAPTALDH1A1
SCHEMBL11738365 0.78 RAB9A (0.61) NPC1RAB9AHPGDMAPTALDH1A1
SCHEMBL4398615 0.78 ALDH1A1 (0.54) NPC1RAB9AHPGDMAPTALDH1A1
SCHEMBL10542029 0.77 HPGD (0.51) NPC1RAB9AHPGDMAPTALDH1A1
SCHEMBL6614654 0.77 RAB9A (0.60) NPC1RAB9AHPGDMAPTALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2023147336-A2 SMALL MOLECULE MODULATORS OF GPR139 COMPLEX UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) 2023-08-03 WO disclosed
EP-1685100-B1 NOVEL 1, 3-DISUBSTITUTED AZETIDINE DERIVATIVES FOR USE AS 5HT2A RECEPTOR LIGANDS MERCK SHARP & DOHME (GB) 2011-02-09 EP disclosed
CN-1902168-A Novel 1, 3-disubstituted azetidine derivatives as 5-HT 2A receptor ligands MERCK SHARP & DOHME (GB) 2007-01-24 CN disclosed
US-7094777-B2 5-HT2A receptor ligands MERK SHARP & DOHME LTD. 2006-08-22 US disclosed
EP-1685100-A1 NOVEL 1, 3-DISUBSTITUTED AZETIDINE DERIVATIVES FOR USE AS 5HT2A RECEPTOR LIGANDS Merck Sharp & Dohme Limited (GB) 2006-08-02 EP disclosed
WO-2005047246-A1 NOVEL 1, 3-DISUBSTITUTED AZETIDINE DEIVATIVES FOR USE AS 5HT2A RECEPTOR LIGANDS MERCK SHARP & DOHME LIMITED (GB) 2005-05-26 WO disclosed
US-20050101586-A1 Novel 5-HT2A receptor ligands MERCK SHARP & DOHME LTD. (GB) 2005-05-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050101586-A1 Novel 5-HT2A receptor ligands HTR2A, HTR1A, HTR5A NPC1 1858/4885RAB9A 1740/4885HPGD 1331/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.